Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $110.43

Lantheus Holdings, Inc. (NASDAQ:LNTH) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $110.4286.

Several equities research analysts recently commented on the stock. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. B. Riley Financial boosted their price target on Lantheus from $97.00 to $129.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Truist Financial raised their price objective on Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th.

Hedge Funds Weigh In On Lantheus

Hedge funds have recently bought and sold shares of the company. Western Wealth Management LLC bought a new stake in Lantheus during the 1st quarter valued at about $25,000. Smartleaf Asset Management LLC lifted its stake in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the second quarter valued at approximately $36,000. Finally, Bessemer Group Inc. grew its holdings in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $104.61 on Friday. The stock has a fifty day simple moving average of $103.00 and a two-hundred day simple moving average of $85.17. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The company has a market cap of $6.81 billion, a price-to-earnings ratio of 25.21 and a beta of -0.06. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus will post 4.5 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.